For selected applicants, the agency plans to cut review times down to one to two months and provide "tumor board-style" ...

Archeus hopes to begin a Phase I trial of the PSMA-targeted agent in metastatic, castration-resistant prostate cancer later this year.

The agency maintains that the beta-amyloid-targeting drugs show too limited benefit to justify their cost to the National Health Service.